VitaSpring Biomedical Co. Ltd
VitaSpring Biomedical Co. Ltd., a development-stage biomedical company, engages in the research, development, and commercialization of wellness and healthy lifestyle products. The company focuses on the development of cell-based medical technologies for use in regenerative medicine, preventive health care, beauty, and anti-aging applications. It is also involved in the development of cell medicin… Read more
VitaSpring Biomedical Co. Ltd (VSBC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of October 2022: 0.001x
Based on the latest financial reports, VitaSpring Biomedical Co. Ltd (VSBC) has a cash flow conversion efficiency ratio of 0.001x as of October 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.46K) by net assets ($1.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
VitaSpring Biomedical Co. Ltd - Cash Flow Conversion Efficiency Trend (2017–2026)
This chart illustrates how VitaSpring Biomedical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
VitaSpring Biomedical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VitaSpring Biomedical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EcoGraf Ltd
F:FMK
|
-0.018x |
|
199430
KQ:199430
|
0.049x |
|
Bank Artha Graha Internasional
JK:INPC
|
0.010x |
|
DOFRB
IS:DOFRB
|
-0.438x |
|
Saturn Metals Ltd
AU:STN
|
-0.021x |
|
Graphisoft Park SE Real Estate Development European Company Limited
F:GUV
|
-0.025x |
|
NISSHIN GROUP HOLDINGS Company Limited
MU:NFU
|
N/A |
|
Magyar Bancorp Inc
NASDAQ:MGYR
|
0.030x |
Annual Cash Flow Conversion Efficiency for VitaSpring Biomedical Co. Ltd (2017–2026)
The table below shows the annual cash flow conversion efficiency of VitaSpring Biomedical Co. Ltd from 2017 to 2026.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-01-31 | $-2.40 Million | $-77.56K | 0.032x | 0.00% |
| 2023-01-31 | $-2.40 Million | $-77.56K | 0.032x | -39.80% |
| 2022-01-31 | $1.58 Million | $84.81K | 0.054x | +112.30% |
| 2021-01-31 | $96.36K | $-42.13K | -0.437x | -- |
| 2020-01-31 | $0.00 | $-105.00 | x | -- |
| 2019-01-31 | $-6.92K | $-34.25K | 4.950x | +4320.33% |
| 2018-01-31 | $-3.42K | $401.00 | -0.117x | +91.43% |
| 2017-01-31 | $2.96K | $-4.04K | -1.369x | -- |